Skip to main content

Table 2 Table showing localisation of recurrence, pathologic and treatment characteristics and outcome of patients with local and metastatic recurrence

From: Outcome of recurrent and metastatic small cell carcinoma of the bladder

Localisation of recurrence

Histology (Mixed or pure SmCC)

Treatment

Response

Survival (months)

Death

Rectum

mixed

Surgery + CT (3EP) + RT

Progressive

7.1

yes

Neo-bladder

Mixed

CT (6MVAC)

PR < 50%

10

yes

RP

Pure

CT (4EP)

Stable

5.5

yes

RP

Mixed

RT (Y 45 Gy) + chemotherapy (4G)

Stable

7.7

yes

RP

Mixed

CT (4GC) + RT (Y 45 Gy)

CR

28.8

yes

CNS

Pure

CT (1 EP + 1 MTX intrathecal)

-

0.4

yes

CNS

Pure

RT (30 Gy)

Progressive

3.7

yes

Liver and RP

Mixed

CT (1GC)

Progressive

0.7

yes

Liver and RP

Mixed

CT (4G)

Progressive

3.1

yes

Liver and Bone

Pure

CT (6EP)

PR > 50%

20.3

no

Lung and RP

Mixed

CT (6EP)

PR > 50%

14.7

no

Lung

Mixed

CT (6EP in first line and 6GC in second line)

PR > 50% (in first line)

26.3

yes

  1. SmCC = small cell carcinoma; CNS = central nervous system; RP = retroperitoneal; EP = etoposide and cisplatin; G = gemcitabine; GC = gemcitabine plus cisplatin; MVAC = methotrexate, vinblastine, doxorubicin and cisplatin; MTX = methotrexate; CT = chemotherapy; RT = radiotherapy; Y = Y field radiotherapy; PR = partial response; CR = complete response, NA = not applicable